Month: January 2021

Jan 25 2021

Uncategorized

New project to investigate a promising drug target for treatment of schizophrenia

by Clinical Editor

No Comments

A partnership between the University of Oxford, Earlham Institute (EI), and global pharmaceutical companies Biogen Inc and Boehringer Ingelheim will investigate a promising new drug target for the …

Jan 25 2021

Uncategorized

Investigating new treatment for schizophrenia as first Psychiatry Consortium funded project announce

by Clinical Editor

No Comments

A partnership between the University of Oxford, Earlham Institute (EI), and global pharmaceutical companies Biogen Inc and Boehringer Ingelheim will investigate a promising new drug target for the …

Jan 25 2021

Uncategorized

Increased risk of Parkinson’s disease in patients with schizophrenia

by Clinical Editor

No Comments

A new study conducted at the University of Turku, Finland, shows that patients with a schizophrenia spectrum disorder have an increased risk of Parkinson’s disease later in life. The increased...

Jan 25 2021

Uncategorized

Psychiatric Nurses’ Perceptions of Therapeutic Alliance With the Schizophrenia Population: A Survey Study

by Clinical Editor

No Comments

Research on nurse–patient relationships with the schizophrenia population is sparse. The current study piloted a survey to explore therapeutic relationships. Fifty-one psychiatric nurses completed an …

Jan 25 2021

Uncategorized

Parkinson’s disease may up schizophrenia risk: Study

by Clinical Editor

No Comments

Patients with a schizophrenia spectrum disorder have an increased risk of Parkinson’s disease later in life. The study indicates that the increased risk may be due to alterations in the...

Jan 24 2021

Uncategorized

New project to investigate a promising drug target for treatment of schizophrenia

by Clinical Editor

No Comments

A partnership between the University of Oxford, Earlham Institute (EI), and global pharmaceutical companies Biogen Inc and Boehringer Ingelheim will investigate a promising new drug target for the …

Jan 24 2021

Uncategorized

Investigating new treatment for schizophrenia as first Psychiatry Consortium funded project announce

by Clinical Editor

No Comments

A partnership between the University of Oxford, Earlham Institute (EI), and global pharmaceutical companies Biogen Inc and Boehringer Ingelheim will investigate a promising new drug target for the …

Jan 24 2021

Uncategorized

Psychiatric Nurses’ Perceptions of Therapeutic Alliance With the Schizophrenia Population: A Survey Study

by Clinical Editor

No Comments

Research on nurse–patient relationships with the schizophrenia population is sparse. The current study piloted a survey to explore therapeutic relationships. Fifty-one psychiatric nurses completed an …

Jan 24 2021

Uncategorized

Increased risk of Parkinson’s disease in patients with schizophrenia

by Clinical Editor

No Comments

A new study conducted at the University of Turku, Finland, shows that patients with a schizophrenia spectrum disorder have an increased risk of Parkinson’s disease later in life. The increased...

Jan 24 2021

Uncategorized

Parkinson’s disease may up schizophrenia risk: Study

by Clinical Editor

No Comments

Patients with a schizophrenia spectrum disorder have an increased risk of Parkinson’s disease later in life. The study indicates that the increased risk may be due to alterations in the...